Katasonow A B, Brusow O S, Beljaew B S, Slobina G P, Faktor M I, Larionowa T B, Trunte K, Lidemann R R
Institut für Klinische Psychiatrie, Akademie der Medizinischen Wissenschaften der UdSSR.
Psychiatr Neurol Med Psychol (Leipz). 1989 Apr;41(4):210-7.
The inhibitory potencies of imipramine (IC50-values for IMI) and trazodone (IC50-values for TRA) on platelet [3H]serotonin uptake were measured in depressed patients. The IC50-values for IMI in patients was shown to be higher (P less than 0.01) than in controls. The IC50-values for TRA in patients were lower (P less than 0.01) than found in platelets from controls. These alterations were not accompanied by the significant decrease of a density of platelet [3H]imipramine binding sites. Drug treatment led to the normalization of the IC50-values for IMI and to the partial increase of the IC50-values for TRA. There was a negative correlation of IC50-values for TRA and severity of depressive symptoms evaluated by the Hamilton Depression Rating Scale. The results support the hypothesis that the mechanisms of the regulation of [3H]serotonin uptake sensitivity to IMI and TRA in patients are different.
在抑郁症患者中测定了丙咪嗪（IMI的IC50值）和曲唑酮（TRA的IC50值）对血小板[3H]5-羟色胺摄取的抑制效力。结果显示，患者中IMI的IC50值高于对照组（P<0.01）。患者中TRA的IC50值低于对照组血小板中的IC50值（P<0.01）。这些改变并未伴有血小板[3H]丙咪嗪结合位点密度的显著降低。药物治疗使IMI的IC50值恢复正常，并使TRA的IC50值部分升高。TRA的IC50值与汉密尔顿抑郁量表评估的抑郁症状严重程度呈负相关。这些结果支持以下假设：患者中[3H]5-羟色胺摄取对IMI和TRA敏感性的调节机制不同。
